1. European drug market entries 2015 with new mechanisms of action.
- Author
-
van den Heuvel, Titus W. P., Cohen, Adam F., and Rissmann, Robert
- Subjects
- *
ANTILIPEMIC agents , *ANTIHYPERTENSIVE agents , *DRUG approval , *INVESTIGATIONAL drugs - Abstract
In this article, we consider the new drugs approved for the European market in 2015. We present a summary of the new mechanisms of action introduced and highlight three new mechanisms of action with a potentially high future impact: PCSK9 inhibition (alirocumab (Praluent®) and evolocumab (Repatha®)) for hypercholesterolaemia, neprilysin inhibition (sacubitril in combination with valsartan (Entresto®)) for heart failure, and interleukin-5 inhibition (mepolizumab (Nucala®)) for asthma. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF